Antibiotic resistant bacteria are "sleeper cells" which can survive doses of antibiotics and lie resting in a dormant state, but have the ability to "wake up" and re-infect, research has found.
Antibiotic resistance is one of the most pressing public health challenges and threatens the ability to effectively fight infectious diseases including pneumonia and tuberculosis.
In the study, led by Stefano Pagliara, a biophysicist at the University of Exeter, the team used a miniaturised device which enabled them to isolate and study single bacteria over time.
Next, the team dosed bacteria with ampicillin. They found that the vast majority of the 1.3 per cent of cells that survived were live but non-growing.
These are "sleeper cells" because they look dormant and resemble the cells killed by antibiotics, but are potentially dangerous with the ability to "wake up" and re-infect humans or animals, Pagliara said, in the paper published in the journal BMC Biology.
Besides, these "sleeper cells", the researchers also found "persister cells", which accounted for less than one third of surviving cells and started regrowing after the course of antibiotics ended.
Both groups shared similar features suggesting that the two populations of cells are linked. Their unique fluorescence meant they could both be spotted even before being dosed with antibiotics.
But because "sleeper cells" are non-growing, standard detection methods cannot differentiate them from dead cells, giving the false impression that far fewer cells have survived a course of antibiotics.
"Unlike persister cells which quickly resume growth after the antibiotic course ends, 'sleeper cells' remain non-growing for prolonged periods of time, and elude detection using traditional methods.
"Our research should make it easier to develop biomarkers to isolate these cells and open up new ways to map the biochemical makeup of bacteria that can escape antibiotics, so we can find ways of targeting them effectively," Pagliara added.
--IANS
rt/ksk/bg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
